

**Catalogue de documents pour le chercheur****Titre du document / Document title**

Combretastatin A-4 phosphate as a tumor vascular-targeting agent : Early effects in tumors and normal tissues

**Auteur(s) / Author(s)**

TOZER G. M. (1) ; PRISE V. E. (1) ; WILSON J. (1) ; LOCKE R. J. (1) ; VOJNOVIC B. (1) ; STRATFORD M. R. L. (1) ; DENNIS M. F. (1) ; CHAPLIN D. J. (1) ;

**Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)**

(1) Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, ROYAUME-UNI

**Résumé / Abstract**

The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-O-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which by 6 h was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, N[ω]-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed *in vivo*. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.

**Revue / Journal Title**

Cancer research (Cancer res.) ISSN 0008-5472 CODEN CNREA8

**Source / Source**

1999, vol. 59, n°7, pp. 1626-1634 (43 ref.)

**Langue / Language**

Anglais

**Editeur / Publisher**

American Association for Cancer Research, Philadelphia, PA, ETATS-UNIS (1941) (Revue)

**Mots-clés anglais / English Keywords**

Blood vessel ; Tumoral tissue ; Rat ; Animal ; Mechanism of action ; Spindle cell carcinoma ; Blood ; Biological fluid ; Intraperitoneal administration ; Treatment ; Biological activity ; Blood flow ; Arterial pressure ;

Rodentia ; Mammalia ; Vertebrata ; Malignant tumor ;

**Mots-clés français / French Keywords**

Vaisseau sanguin ; Tissu tumoral ; Rat ; Animal ; Mécanisme action ; Carcinosarcome ; Sang ; Liquide biologique ; Voie intrapéritonéale ; Traitement ; Activité biologique ; Débit sanguin ; Pression artérielle ; Combretastatine A4 ; Rodentia ; Mammalia ; Vertebrata ; Tumeur maligne ;

002b02r02 ;

**Mots-clés espagnols / Spanish Keywords**

Vaso sanguíneo ; Tejido tumoral ; Rata ; Animal ; Mecanismo acción ; Carcinoma fusocelular ; Sangre ; Líquido biológico ; Vía intraperitoneal ; Tratamiento ; Actividad biológica ; Flujo sanguíneo ; Presión arterial ; Rodentia ; Mammalia ; Vertebrata ; Tumor maligno ;

**Localisation / Location**

INIST-CNRS, Cote INIST : 5088, 35400008346620.0400

**Copyright 2006 INIST-CNRS. All rights reserved**

Toute reproduction ou diffusion même partielle, par quelque procédé ou sur tout support que ce soit, ne pourra être faite sans l'accord préalable écrit de l'INIST-CNRS.

No part of these records may be reproduced or distributed, in any form or by any means, without the prior written permission of INIST-CNRS.

Nº notice refdoc (ud4) : 1739015

Day : Saturday  
Date: 3/3/2007  
Time: 14:57:38

## PALM INTRANET

# Inventor Information for 10/602325

Inventor Name	City	State/Country
CHAPLIN, DAVID	WATLINGTON	UNITED KINGDOM
YOUNG, SCOTT	STOWE	MASSACHUSETTS

[Appn Info](#) [Contents](#) [Petition Info](#) [Atty/Agent Info](#) [Continuity/Reexam](#) [Foreign](#)

Search Another: Application#   or Patent#    
PCT /  /   or PG PUBS #    
Attorney Docket #    
Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page